May be safely administered with other heart medications (i.e. cardiac glycoside preparations)
Is well tolerated
Is suitable for long-term therapy

For minor heart conditions

As effective as ACE-Inhibitors/Diuretics

In a comparative study 216 patients suffering from cardiac insufficiency according to NYHA stage II were treated either with Cralonin or with ACE Inhibitors/ACE inhibitors plus diuretics. The global therapy result for Cralonin was estimated as very good or good in 86% of the cases (only 67% in ACE-Inhibitor group). The study revealed that Cralonin reduces the power-frequency product to the same extent as ACE Inhibitors/diuretics. The effect on investigated symptoms like reduced output, feeling of exhaustion, easy fatiguability, dyspnea on exertion, pretibial oedema was comparable (see illustration below).

Areas of application

<table>
<thead>
<tr>
<th>Constituents</th>
<th>Patient groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crataegus oxyacantha (whitethorn)</td>
<td>Senior persons</td>
</tr>
<tr>
<td>Spigelia (Indian pink)</td>
<td>Athletes, work-stressed persons, the elderly</td>
</tr>
</tbody>
</table>

Cardiac disorders, collection of fluid in tissues, and general weakened conditions

| Potassium carbonicum (potassium carbonate) | Elderly persons and/or persons with circulatory weaknesses, especially following infectious processes |

Constituents

Crataegus oxyacantha (whitethorn)
Spigelia (Indian pink)
Potassium carbonicum (potassium carbonate)

References:
1) Zenner S, Borho B, Metelmann H. Biological Cardiac Therapy with Cralonin: Results of a Study on Multicentric Application with 2,178 Patients. Biological Therapy 1991, Vol IX, No. 3: 146-150, 166-168
3) Publication in European Journal of Heart Failure in preparation

Cralonin®
Drops · Injection solution
Composition: Drops: 100 ml cont.: Crataegus Ø 70 ml; Spigelia D3, Kalium carbonicum D3 1 ml each. Contains 45 vol.-% alcohol. Injection solution: 1 ml cont.: Crataegus D2 8.8 µl; Spigelia D3, Kalium carbonicum D2 1.1 µl each.

Indications: Drops: Gastrocardiac, sequelae of myocardial damage, nervous cardiac disorders, piercing cardiac pain, and cardiac pain of other types (e.g. angina pectoris). Injection solution: Coronary insufficiency, angina pectoris, piercing cardiac pain, cardiac pain of other types, infectious-toxic myocardial insufficiency, status following myocardial infarction. Contraindications: None known. Side effects: None known. Interactions with other medications: None known. Dosage: The physician should determine dosage in accordance with the individual needs of the patient. Drops: Typical dosage for long term therapy: 10-20 drops 3 times a day. Injection solution: 1 ampoule daily (maximum every 8 hours), otherwise 1 ampoule 3-4 times weekly. i.m., i.d., i.v.

Package sizes: Drops: Drop bottles containing 30 and 100 ml. Injection solution: Packs containing 10, 50 and 100 ampoules of 1.1 ml.

Revised: January 2003
Every 2nd death in Germany is attributed to heart diseases. Furthermore, in addition to being life-threatening, heart disease is also life-altering. Patients’ quality of life is adversely affected by shortness of breath, chest pain, oedema, impaired exercise capacity, and leg cramps.

Unsatisfactory results with conventional treatment alone are widespread – many patients with heart diseases are therefore eager to try alternative treatments.

The homoeopathic combination preparation Cralonin can alleviate cardiac disorders, such as: 1,2,3

- Cardiac insufficiency (NYHA stages I + II)
- Symptoms of angina pectoris
- Post myocardial infarction
- Cardiodynia
- Infectious-toxic myocardial insufficiency